Antisense Financial Statements From 2010 to 2024
| ATHJF Stock | USD 0.04 0.00 0.00% |
Check Antisense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Antisense Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Antisense financial statements analysis is a perfect complement when working with Antisense Therapeutics Valuation or Volatility modules.
Antisense |
Antisense Therapeutics Limited Company Shares Outstanding Analysis
Antisense Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Antisense Therapeutics Shares Outstanding | 669.04 M |
Most of Antisense Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Antisense Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Antisense Therapeutics Limited has 669.04 M of shares currently outstending. This is 270.59% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all United States stocks is 17.0% lower than that of the firm.
Antisense Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Antisense Therapeutics's current stock value. Our valuation model uses many indicators to compare Antisense Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Antisense Therapeutics competition to find correlations between indicators driving Antisense Therapeutics's intrinsic value. More Info.Antisense Therapeutics Limited is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Antisense Therapeutics' earnings, one of the primary drivers of an investment's value.About Antisense Therapeutics Financial Statements
Antisense Therapeutics stakeholders use historical fundamental indicators, such as Antisense Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Antisense Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Antisense Therapeutics' assets and liabilities are reflected in the revenues and expenses on Antisense Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Antisense Therapeutics Limited. Please read more on our technical analysis and fundamental analysis pages.
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia. Antisense Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Antisense Pink Sheet
Antisense Therapeutics financial ratios help investors to determine whether Antisense Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antisense with respect to the benefits of owning Antisense Therapeutics security.